- Presenting at JMP Securities Life Sciences Conference 2015 -
- Participating in 2nd Annual ROTH Healthcare Corporate Access Day -
LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 16, 2015--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the
Company will present at the JMP Securities Life Sciences Conference 2015
on Tuesday, June 23rd at 12:30 p.m. (ET) in New York.
A live audio webcast
and replay of the presentation will be available on the "Investors"
section of the Company's website, www.syntapharma.com.
Synta will also be participating in the 2nd Annual ROTH Healthcare
Corporate Access Day on Wednesday, June 24th in
London. There is no formal presentation during the conference, however,
management will be available for one-on-one meetings.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical
company focused on research, development and commercialization of novel
oncology medicines that have the potential to change the lives of cancer
patients. Synta’s lead oncology drug candidate, ganetespib, a novel heat
shock protein 90 (Hsp90) inhibitor, is currently being evaluated in
several clinical trials including the pivotal GALAXY-2 Phase 3 trial in
non-small cell lung cancer. Building on its extensive expertise in the
science of Hsp90, Synta also has a novel proprietary Hsp90 inhibitor
Drug Conjugate (HDC) small molecule drug development program. IND
enabling studies have commenced for the first clinical candidate from
the HDC program, STA-12-8666, and preclinical evaluation of additional
HDC candidates is ongoing. For more information, please visit www.syntapharma.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150616006648/en/
Source: Synta Pharmaceuticals Corp.
Investors:
Synta Pharmaceuticals Corp.
Daniel Cole,
781-541-7250
[email protected]
or
Argot
Partners
Andrea Rabney, 212-600-1494
[email protected]
or
Media:
Argot
Partners
Eliza Schleifstein, 917-763-8106
[email protected]
